Edwards Lifesciences

Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » Altro su finance.yahoo.com

Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Altro su de.investing.com

Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » Altro su de.investing.com